TITLE

Generic Drugs Face Regulatory and Scientific Challenges

AUTHOR(S)
Wechsler, Jill
PUB. DATE
August 2013
SOURCE
BioPharm International;Aug2013, Vol. 26 Issue 8, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article discusses legislative, regulatory and scientific challenges facing the generic drugs sector. The developments in the sector as the U.S. Food and Drug Administration (FDA) celebrates the one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 are discussed. The GDUFA steering committee is shifting its focus to enhance the generic-drug review performance to meet the performance commitments.
ACCESSION #
89689942

 

Related Articles

  • Woodcock cites generic skepticism as priority. J. G. D. // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p14 

    The article reports that the U.S. Food and Drug Administration (FDA) director of drug evaluation and research Janet Woodcock prioritizes on the increasing skepticism on generic drugs's therapeutic equivalence. It notes that the equivalence issues between generics and innovator drugs have been...

  • Confidence in Generic Drug Substitution. Lionberger, R; Jiang, W; Huang, S‐M; Geba, G // Clinical Pharmacology & Therapeutics;Oct2013, Vol. 94 Issue 4, p438 

    Patients should have confidence that the generic drugs they are prescribed in the United States can be effectively substituted for the brand product or another generic product. Through new bioequivalence study designs for narrow therapeutic index (NTI) drugs and postapproval studies of generic...

  • First-time generic approvals.  // Formulary;Feb2004, Vol. 39 Issue 2, p80 

    Presents first-time generic approvals by the U.S. Food and Drug Administration as of February 2004. Fenoldopam injection; Amiodarone tablets; Amoxicillin tablets; Others.

  • Update.  // Medical Marketing & Media;Sep2004, Vol. 39 Issue 9, p17 

    The article presents information related to the pharmaceutical industries. The U.S. Food and Drug Administration (FDA) has announced that it wants to replace approvable and not approvable letters in new and generic drug reviews with complete response letters that give companies specific...

  • WHY YOUR MEDICINE COSTS SO MUCH. Guest, Jim // Consumer Reports;Nov2006, Vol. 71 Issue 11, p2 

    This article presents information about why generic drug prices might not be as low as they could be and how pharmaceutical companies are delaying the release of some generics to stores. The U.S. Food and Drug Administration (FDA) allows any person or company to file a petition challenging...

  • Biogenerics bill gains momentum in Congress.  // Drug Store News;6/25/2007, Vol. 29 Issue 8, p10 

    The article reports on the efforts of generic drug industry and its chief umbrella organization Generic Pharmaceutical Association for the creation of a biogeneric approval pathway at the U.S. Food and Drug Administration (FDA) a top priority for 2007. The coalition of retailers and companies...

  • New FDA Guidance on Polymorphic Compounds in Generic Drugs. Hoffman, Michelle // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p26 

    The article reports on the new guidance issued by the U.S. Food and Drug Administration on July 9, 2007. The new guidance advises companies on how to treat polymorphic drug compounds, those that exhibit multiple structural forms. Furthermore, the guidance pertains to orally available drugs that...

  • FDA: Generics Save. J. W. // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p34 

    The article discusses a report issued by the U.S. Food and Drug Administration's (FDA) Office of Generic Drugs, which documents the importance of multiple generic products. According to the report, generic drugs reduce prescription drug prices. The report which was based on the IMS retail data...

  • FDA to Speed Generics. Vastag, Brian // JAMA: Journal of the American Medical Association;7/16/2003, Vol. 290 Issue 3, p324 

    Informs of new regulations and internal reform pertaining to the United States Food and Drug Administration in July 2003. The 30-day limit on generic drugs allowed on the market when there is a patent challenge; Indication that 40 new generic drug experts will be hired with money from the 2004...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics